| Literature DB >> 36034546 |
Nicolas Terliesner1, Nadine Unterwalder2, Anke Edelmann2, Victor Corman3,4, Andreas Knaust2, Leonard Rosenfeld1, Alexander Gratopp1, Hannelore Ringe1, Luise Martin1, Horst von Bernuth1,2,4,5, Marcus A Mall1,4, Tilmann Kallinich1,4,6.
Abstract
Background: Non-pharmaceutical interventions (NPI) during the COVID-19 pandemic aimed at prevention of SARS-CoV-2 transmission also influenced transmission of viruses other than SARS-CoV-2. The aim of this study was to describe and compare the burden of common viral respiratory and gastrointestinal infections in children admitted to Berlin University Children's Hospital (BCH) before and during the COVID-19 pandemic at different levels of public NPI measures.Entities:
Keywords: Bocavirus; COVID-19; RSV; child; gastrointestinal infection; non-pharmaceutical interventions (NPI); pandemic; respiratory virus infection
Year: 2022 PMID: 36034546 PMCID: PMC9403271 DOI: 10.3389/fped.2022.935483
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.569
Figure 1Chronology of NPI, traveling, SARS-CoV-2 detection rate in Berlin, and normalized virus detection rate at BCH between January 2020 and January 2021; (A) chronology of public regulations in public buildings/spaces, restaurants and night life, private and public gatherings, workplace, school, and kindergartens in Berlin; (B) numbers (106) of flight passengers and overnight stays in hotels per month in Berlin; (C) rate of SARS-CoV-2 infections (104 per month) in Berlin; (D) max-normalized rate of infections (per month) with BoV, CoV, RSV, and PIV in hospitalized patients at BCH.
Figure 2Total monthly number of hospitalized patients at BCH tested for respiratory viruses and for RoV and AdV, respectively. Blue line: mean 2016-2019, blue shade: 95% confidence interval 2016-2019, green line: absolute number per month from 2020, calendar months 2016-2019 are shown as a historical reference and correspond to calendar months, not to year on x-axis. (A) Total number of patients per month with molecular biology testing of respiratory samples for respiratory viruses; (B) total number of patients per month with EIA or molecular biology testing of stool sample for RoV; (C) total number of patients per month with molecular biology testing of stool sample for AdV.
Figure 3Monthly number of hospitalized patients at BCH positively tested for respiratory viruses. Blue line: mean 2016-2019, blue shade: 95% confidence interval 2016-2019, green line: absolute number per month from 2020, calendar months 2016-2019 are shown as a historical reference and correspond to calendar months, not to year on x-axis. Number of patients per month with respiratory sample tested positive for BoV, CoV, InV, MPV, RSV, PIV, or RV/EV.
Figure 4Monthly number of hospitalized patients at BCH positively tested for gastrointestinal viruses. Blue line: mean 2016-2019, blue shade: 95% confidence interval 2016-2019, green line: absolute number per month from 2020, calendar months 2016-2019 are shown as a historical reference and correspond to calendar months, not to year on x-axis. Number of patients per month with stool sample tested positive for RoV or AdV.
Overview of viruses considered in this study.
|
|
|
|
|
|---|---|---|---|
| Adenoviruses | AdV | 90–100 | No |
| Human Bocavirus | BoV | 20 | No |
| Coronaviruses (229E, NL63, HKU1, OC43) | CoV | 80–120 | Yes |
| Influenzaviruses | InV | 80–120 | Yes |
| Human Metapneumovirus | MPV | 150–600 | Yes |
| Parainfluenzaviruses | PIV | 150–250 | Yes |
| Respiratory Syncytial viruses | RSV | 120–300 | Yes |
| Rhino-/Enteroviruses | RV/EV | 20–30 | No |
| Rotavirus | RoV | 70 | No |